Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence